Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SSS67 Injection
SSS67 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| SSS67 1mg/kg | EXPERIMENTAL | This is a single-dose group. 2 participants will be enrolled and receive a single intravenous infusion of SSS67 at 1 mg/kg on Day 1. No placebo is administered in this group. |
| SSS67 5mg/kg+Placebo | EXPERIMENTAL | This is a single-dose group. 10 participants will be enrolled: 8 receive a single intravenous infusion of SSS67 at 5 mg/kg on Day 1, and 2 receive matching placebo on Day 1. |
| SSS67 15mg/kg+Placebo | EXPERIMENTAL | This is a single-dose group. 10 participants will be enrolled: 8 receive a single intravenous infusion of SSS67 at 15 mg/kg on Day 1, and 2 receive matching placebo on Day 1. |
| SSS67 30mg/kg+Placebo | EXPERIMENTAL | This is a single-dose group. 10 participants will be enrolled: 8 receive a single intravenous infusion of SSS67 at 30 mg/kg on Day 1, and 2 receive matching placebo on Day 1. |
| SSS67 45mg/kg+Placebo | EXPERIMENTAL | This is a single-dose group. 10 participants will be enrolled: 8 receive a single intravenous infusion of SSS67 at 45 mg/kg on Day 1, and 2 receive matching placebo on Day 1. |
| SSS67 60mg/kg+Placebo | EXPERIMENTAL | This is a single-dose group. 10 participants will be enrolled: 8 receive a single intravenous infusion of SSS67 at 60 mg/kg on Day 1, and 2 receive matching placebo on Day 1. |
| Name | Type | Description |
|---|---|---|
| SSS67 Injection | DRUG | In this Phase 1 single ascending dose trial, SSS67 Injection will be administered via intravenous infusion. |
| Placebo | DRUG | Participants will receive a single dose of matching placebo in accordance with their randomly assigned treatment group. |
Inclusion Criteria: * Participants aged 18 to 65 years (inclusive), regardless of gender. * Participate in the clinical trial voluntarily and provide informed consent form. * At screening, body weight ≥ 50 kg for males and ≥ 45 kg for females. Body Mass Index (BMI) must be between 18.5 and 32 kg/m²...
SSS67 is an investigational small molecule being studied in healthy adult participants. It is administered as a single intravenous infusion. The drug is currently in Phase 1 clinical development, and its safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity are being evaluated in a clinical trial.
SSS67 is being developed by Sunshine Biopharma Inc., a company traded under the ticker symbol SBFM. The company is conducting a Phase 1 clinical trial to evaluate the drug in healthy participants.
SSS67 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 trial is currently planned to assess its safety, tolerability, and other characteristics in healthy adult participants.
SSS67 is involved in one clinical trial with the identifier NCT07487545. The trial is titled 'Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SSS67 in Healthy Adult Participants Via Single Intravenous Infusion.' It is a Phase 1, randomized, double-blind, controlled study with an enrollment of 52 participants.
Yes, SSS67 is also known as SSS67 Injection. The drug is administered as a single intravenous infusion, and the alternative name reflects its formulation as an injectable product.